The bill changes rules for required studies of drugs in children. Before taking enforcement action for missed study requirements, the FDA would have to send a notice, allow 45 days for a written response, and decide whether the drug sponsor lacked due diligence. Enforcement would not apply to a drug that is no longer marketed. The bill also requires FDA reports on penalties and compliance with study deadlines.
For orphan drugs, pediatric study requirements would apply when the FDA finds that the assessments could offer a meaningful therapeutic benefit. The bill directs the FDA to issue guidance, hold a public meeting, and maintain lists of conditions that qualify for full waivers. It also calls for a later review of the changes and preserves requirements for studies of molecularly targeted pediatric cancer drugs. For fiscal years 2026 through 2030, the NIH Director may make up to 1% of certain pediatric research funding available for this program.
Drug sponsors would receive a notice and a chance to respond before certain enforcement actions. Children and families may be affected by changes to pediatric study requirements and drug information, but the bill does not specify particular medicines or patient outcomes.
The bill does not state total expenses or provide a specific dollar amount. It authorizes the NIH Director to make up to 1% of certain amounts already made available for pediatric research available for this program in fiscal years 2026 through 2030.
No publicly available information.
No publicly available information.